Angiotensin blockade in late autosomal dominant polycystic kidney disease

New England Journal of Medicine

Volumn 371, Issue 24, 2014, Pages 2267-2276

  Torres, Vicente E ^a   Abebe, Kaleab Z ^b   Chapman, Arlene B ^c   Schrier, Robert W ^d   Braun, William E ^e   Steinman, Theodore I ^f   Winklhofer, Franz T ^h   Brosnahan, Godela ^d   Czarnecki, Peter G ^f   Hogan, Marie C ^a   Miskulin, Dana C ^g   Rahbari Oskoui, Frederic F ^c   Grantham, Jared J ^h   Harris, Peter C ^a   Flessner, Michael F ⁱ   Moore, Charity G ^b   Perrone, Ronald D ^g  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; LISINOPRIL; PLACEBO; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; ALDOSTERONE URINE LEVEL; ARTERIAL PRESSURE; ARTICLE; BODY SURFACE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; END STAGE RENAL DISEASE; EXCRETION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEMATURIA; HOSPITALIZATION; HUMAN; HYPERKALEMIA; INCIDENCE; KIDNEY COLIC; KIDNEY DISEASE; KIDNEY HEMORRHAGE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROLITHIASIS; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN; QUALITY OF LIFE; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; URINARY TRACT DISEASE; ADOLESCENT; ALBUMINURIA; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECTS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; ALBUMINURIA; ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LISINOPRIL; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84918564157     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1402686     Document Type: Article

References (35)

1. Grantham JJ. Autosomal dominant polycystic kidney disease. N Engl J Med 2008;359: 1477-85.
2. Schrier RW. Renal volume, reninangiotensin- aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2009;20: 1888-93.
3. Graham PC, Lindop GB. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 1988;33: 1084-90.
4. Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323: 1091-6.
5. Torres VE, Wilson DM, Burnett JCJ Jr, Johnson CM, Offord KP. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 1991;66: 1010-7.
6. Torres VE, Donovan KA, Scicli G, et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycys- tic kidney disease. Kidney Int 1992;42: 364-73.
7. Loghman-Adham M, Soto CE, Inagami T, Cassis L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2004;287: F775-F788.
8. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311: 507-20.
9. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012;2: 337-414.
10. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334: 939-45.
11. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000;35: 427-32.
12. van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RG. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003;18: 2314-20.
13. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level metaanalysis. Ann Intern Med 2003;139: 244-52.
14. Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2008;23: 573-9.
15. Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. DOI: 10.1056/NEJMoa1402685.
16. Chapman AB, Torres VE, Perrone RD, et al. The HALT polycystic kidney disease trials: Design and implementation. Clin J Am Soc Nephrol 2010;5: 102-9.
17. Torres VE, Chapman AB, Perrone RD, et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 2012;81: 577-85.
18. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994;343: 824-7.
19. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145: 247-54. [Erratum, Ann Intern Med 2008;149: 519.]
20. Vonesh EF, Greene T, Schluchter MD. Shared parameter models for the joint analysis of longitudinal data and event times. Stat Med 2006;25: 143-63.
21. Prentice RL, Williams J, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika 1981;68: 373-9.
22. Seber GAF, Wild CJ. Nonlinear regression. New York: John Wiley, 1989.
23. Demets DL. Group sequential procedures: Calendar versus information time. Stat Med 1989;8: 1191-8.
24. Klahr S, Breyer JA, Beck GJ, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 1995;5: 2037-47.
25. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;363: 830-40. [Errata, N Engl J Med 2010;363: 1190, 1977.]
26. Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: A meta-analysis. Am J Hypertens 2013;26: 424-41.
27. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148: 30-48.
28. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabet Med 2007; 24: 486-93.
29. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 2006;48: 8-20.
30. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual reninangiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62: 1020-5.
31. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547-59.
32. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008;372: 547-53.
33. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369: 1892-903.
34. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367: 2204-13.
35. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367: 2407-18.